Search
for
Sort by
Research 511–540 of 1000+
- WS PRO 160 I 120 mg (a combination of sabal and urtica extract) in patients with LUTS related to BPH
- PD19-08 MARIJUANA, ALCOHOL, ED AND DEPRESSION: EPIDEMIOLOGIC CORRELATIONS WITH BPH/LUTS
- Comparative Effect of Finasteride and Dutasteride on Chromogranin A Levels
- Persistent Sexual and Psychological Symptoms After Finasteride Discontinuation: A Cross-Sectional Observational Study
- The relationship of depression, alcohol and marijuana with treatment for LUTS/BPH.
- Generation of comparative pharmacophoric model for steroidal 5α-reductase I and II inhibitors: A 3D-QSAR study on 6-azasteroids
- Co-administration of 5α-reductase Inhibitors Worsens the Adverse Metabolic Effects of Prescribed Glucocorticoids
- Urinary Incontinence due to Overactive Detrusor Muscle: A Rare Side Effect of Venlafaxine
- Medical Therapies for Treatment of BPH: Special Considerations in Elderly Men
- Fixed-dose combination PRO 160/120 of sabal and urtica extracts improves nocturia in men with LUTS suggestive of BPH: re-evaluation of four controlled clinical studies
- Misdiagnosis of eosinophilic cystitis: A case report and literature review
- Anti-inflammatory Effects in LPS-treated RAW 264.7 Cells and the Influences on Drug Metabolizing Enzyme Activities by the Traditional Herbal Formulas, Yongdamsagan-Tang and Paljung-san
- US Food and Drug Administration Warning Regarding Finasteride and Suicidal Ideation: What Should Urologists Know?
- The post-finasteride syndrome: possible etiological mechanisms and symptoms
- Simultaneous spectrophotometric determination of finasteride and tadalafil in recently FDA approved Entadfi™ capsules
- 5α-Reductases In Human Physiology: an Unfolding Story
- Finasteride and sexual side effects
- Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study
- May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?
- Finasteride Use and Risk of Male Breast Cancer: A Case–Control Study Using Individual-Level Registry Data from Denmark, Finland, and Sweden
- Oral Presentations: Abstracts of the Urological Society of Australia and New Zealand Annual Scientific Meeting, 25–28 February 2023, Melbourne, Australia
- Sexual, physical, and overall adverse effects in patients treated with 5α-reductase inhibitors: a systematic review and meta-analysis
- Finasteride versus dutasteride: a real-world economic evaluation.
- Post-finasteride Syndrome: A Review of Current Literature
- Risk of Poor Glycemic Control in Tamsulosin Versus Finasteride Users with Type 2 Diabetes Mellitus
- Design of Nanocrystalline Suspension of Dutasteride for Intramuscular Prolonged Delivery
- Sustainable UV approaches supported by greenness and whiteness assessments for estimating a recently FDA-approved combination for managing urologic disorders: Tukey's test
- 5α-Reductases in Human Physiology: An Unfolding Story
- Saw Palmetto
- Adverse effects of 5α-reductase inhibitors: What do we know, don’t know, and need to know?